Julian Harrison
Stock Analyst at BTIG
(4.50)
# 248
Out of 5,106 analysts
71
Total ratings
59.38%
Success rate
19.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group | Reiterates: Buy | $6 | $2.29 | +162.01% | 1 | Dec 18, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $100 → $118 | $44.46 | +165.41% | 2 | Dec 16, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $5 | $1.65 | +203.03% | 3 | Dec 2, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $25 → $40 | $18.57 | +115.40% | 3 | Nov 26, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $32 → $38 | $10.00 | +280.00% | 2 | Nov 24, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $17 | $2.42 | +602.48% | 4 | Nov 20, 2025 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $42 → $44 | $6.43 | +584.29% | 2 | Nov 14, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $56 → $63 | $31.71 | +98.68% | 3 | Nov 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.60 | +284.62% | 2 | Nov 13, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $35.24 | +39.05% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $32.11 | +89.97% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $88.73 | -7.58% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.60 | +73.91% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.00 | +275.00% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $77.30 | +48.77% | 2 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $16.35 | +71.25% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $120 | $138.35 | -13.26% | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 | $13.74 | +518.63% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $18.67 | +114.25% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $33.23 | +110.65% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $42.30 | -12.53% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.38 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $50.04 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $1.86 | +383.87% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $2.90 | +175.86% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.57 | +1,307.46% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.67 | +22,284.72% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $510.44 | - | 2 | Feb 11, 2022 |
Mereo BioPharma Group
Dec 18, 2025
Reiterates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Nektar Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $100 → $118
Current: $44.46
Upside: +165.41%
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.65
Upside: +203.03%
Theravance Biopharma
Nov 26, 2025
Maintains: Buy
Price Target: $25 → $40
Current: $18.57
Upside: +115.40%
Cullinan Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $10.00
Upside: +280.00%
Rezolute
Nov 20, 2025
Reiterates: Buy
Price Target: $17
Current: $2.42
Upside: +602.48%
Cartesian Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.43
Upside: +584.29%
Oruka Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $56 → $63
Current: $31.71
Upside: +98.68%
Connect Biopharma Holdings
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Liquidia
Nov 4, 2025
Reiterates: Buy
Price Target: $49
Current: $35.24
Upside: +39.05%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $32.11
Upside: +89.97%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $88.73
Upside: -7.58%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $4.60
Upside: +73.91%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.00
Upside: +275.00%
Oct 9, 2025
Reiterates: Buy
Price Target: $115
Current: $77.30
Upside: +48.77%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $16.35
Upside: +71.25%
Oct 7, 2025
Maintains: Buy
Price Target: $112 → $120
Current: $138.35
Upside: -13.26%
Sep 29, 2025
Downgrades: Neutral
Price Target: $85
Current: $13.74
Upside: +518.63%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $18.67
Upside: +114.25%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $33.23
Upside: +110.65%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $42.30
Upside: -12.53%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $21.38
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $50.04
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.86
Upside: +383.87%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.90
Upside: +175.86%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.57
Upside: +1,307.46%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.67
Upside: +22,284.72%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $510.44
Upside: -